Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cariprazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Cariprazine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002327-29 Sponsor Protocol Number: RGH-188-201 Start Date*: 2017-01-05
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Open-Label, Multicentre, Multiple Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Cariprazine in Adolescent Subjects with Schizophrenia, Schizoaffective- and Schizophreniform Di...
    Medical condition: Schizophrenia, Schizoaffective- and Schizophreniform Disorders
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039620 Schizoaffective and schizophreniform disorders HLT
    20.0 100000004873 10039631 Schizophrenia NEC HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002334-39 Sponsor Protocol Number: RGH-MD-56 Start Date*: 2012-04-09
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
    Medical condition: Bipolar I Disorder Major Depressive Episode
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-004590-27 Sponsor Protocol Number: RGH-188-203 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Plc
    Full Title: 2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
    Medical condition: Adolescent patient (13-<18 years of age) with Schizophrenia
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Ongoing) HU (Prematurely Ended) DE (Ongoing) PL (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018405-12 Sponsor Protocol Number: RGH-MD-11 Start Date*: 2010-10-11
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia
    Medical condition: Schizophrenia is a lifelong disabling psychiatric disorder with a reported worldwide prevalence of about 1%.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004006-26 Sponsor Protocol Number: RGH-MD-20 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to...
    Medical condition: Adolescent Patients (13 to 17 years of age) with Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005726-29 Sponsor Protocol Number: CariCog Start Date*: 2021-02-23
    Sponsor Name:Medical University Innsbruck
    Full Title: An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005179-18 Sponsor Protocol Number: RGH-MD-75 Start Date*: 2012-03-12
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000757-13 Sponsor Protocol Number: RGH-MD-54 Start Date*: 2016-06-07
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000803-25 Sponsor Protocol Number: RGH-MD-25 Start Date*: 2019-10-02
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION...
    Medical condition: Bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10026753 Manic and bipolar mood disorders and disturbances HLGT
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000818-34 Sponsor Protocol Number: RGH-MD-24 Start Date*: 2019-10-02
    Sponsor Name:Allergan Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002782-19 Sponsor Protocol Number: 3111-301-001 Start Date*: 2019-10-24
    Sponsor Name:Allergan Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRE...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-016041-25 Sponsor Protocol Number: RGH-MD-36 Start Date*: 2010-05-12
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A Long-Term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder
    Medical condition: Bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-001268-58 Sponsor Protocol Number: 11500/AOGENO/2020 Start Date*: 2021-07-06
    Sponsor Name:Semmelweis University, STIA-POC-2020
    Full Title: Investigation of cellbiological effects of cariprazine in patients with mitochondrial schizophrenia
    Medical condition: Mitochondrial disease associated schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000756-98 Sponsor Protocol Number: RGH-MD-53 Start Date*: 2016-07-19
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003164-31 Sponsor Protocol Number: 3111-302-001 Start Date*: 2019-08-15
    Sponsor Name:Allergan Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRE...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-005485-36 Sponsor Protocol Number: RGH-188-005 Start Date*: 2013-04-17
    Sponsor Name:Gedeon Richter Plc
    Full Title: A kariprazin hatásosságának, biztonságosságának és tolerálhatóságának randomizált, kettős vak, párhuzamos csoportos vizsgálata túlnyomórészt negatív tünetes skizofrén betegeknél
    Medical condition: Patients with Predominant Negative Symptoms of Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002048-29 Sponsor Protocol Number: RGH-MD-06 Start Date*: 2012-03-29
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003434-24 Sponsor Protocol Number: ACP-103-034 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003436-20 Sponsor Protocol Number: ACP-103-038 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003435-38 Sponsor Protocol Number: ACP-103-035 Start Date*: 2017-04-28
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) BG (Ongoing) CZ (Ongoing) DE (Prematurely Ended) LT (Completed) PL (Ongoing) IT (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA